Pharmacogenetic Testing for Prevention of Severe Cutaneous Adverse Drug Reactions

Chih-Jung Chang; Chih-Jung Chang; Chun-Bing Chen; Chun-Bing Chen; Chun-Bing Chen; Chun-Bing Chen; Chun-Bing Chen; Chun-Bing Chen; Shuen-Iu Hung; Shuen-Iu Hung; Chao Ji; Wen-Hung Chung; Wen-Hung Chung; Wen-Hung Chung; Wen-Hung Chung; Wen-Hung Chung; Wen-Hung Chung; Wen-Hung Chung

doi:10.3389/fphar.2020.00969

Frontiers in Pharmacology (Jul 2020)

Pharmacogenetic Testing for Prevention of Severe Cutaneous Adverse Drug Reactions

Chih-Jung Chang,
Chih-Jung Chang,
Chun-Bing Chen,
Chun-Bing Chen,
Chun-Bing Chen,
Chun-Bing Chen,
Chun-Bing Chen,
Chun-Bing Chen,
Shuen-Iu Hung,
Shuen-Iu Hung,
Chao Ji,
Wen-Hung Chung,
Wen-Hung Chung,
Wen-Hung Chung,
Wen-Hung Chung,
Wen-Hung Chung,
Wen-Hung Chung,
Wen-Hung Chung

Affiliations

Chih-Jung Chang: Department of Dermatology and Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Linkou, Taipei and Keelung, Taiwan
Chih-Jung Chang: Central Research Laboratory, Department of Dermatology and Xiamen Chang Gung Allergology Consortium, Xiamen Chang Gung Hospital, School of Medicine, Huaqiao University, Xiamen, China
Chun-Bing Chen: Department of Dermatology and Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Linkou, Taipei and Keelung, Taiwan
Chun-Bing Chen: Central Research Laboratory, Department of Dermatology and Xiamen Chang Gung Allergology Consortium, Xiamen Chang Gung Hospital, School of Medicine, Huaqiao University, Xiamen, China
Chun-Bing Chen: Cancer Vaccine and Immune Cell Therapy Core Laboratory, Department of Medical Research, Chang Gung Memorial Hospital, Taoyuan, Taiwan
Chun-Bing Chen: College of Medicine, Chang Gung University, Taoyuan, Taiwan
Chun-Bing Chen: Whole-Genome Research Core Laboratory of Human Diseases, Chang Gung Memorial Hospital, Keelung, Taiwan
Chun-Bing Chen: Graduate Institute of Clinical Medical Sciences, Chang Gung University, Taoyuan, Taiwan
Shuen-Iu Hung: Department of Dermatology and Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Linkou, Taipei and Keelung, Taiwan
Shuen-Iu Hung: Cancer Vaccine and Immune Cell Therapy Core Laboratory, Department of Medical Research, Chang Gung Memorial Hospital, Taoyuan, Taiwan
Chao Ji: Department of Dermatology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China
Wen-Hung Chung: Department of Dermatology and Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Linkou, Taipei and Keelung, Taiwan
Wen-Hung Chung: Central Research Laboratory, Department of Dermatology and Xiamen Chang Gung Allergology Consortium, Xiamen Chang Gung Hospital, School of Medicine, Huaqiao University, Xiamen, China
Wen-Hung Chung: Cancer Vaccine and Immune Cell Therapy Core Laboratory, Department of Medical Research, Chang Gung Memorial Hospital, Taoyuan, Taiwan
Wen-Hung Chung: College of Medicine, Chang Gung University, Taoyuan, Taiwan
Wen-Hung Chung: Whole-Genome Research Core Laboratory of Human Diseases, Chang Gung Memorial Hospital, Keelung, Taiwan
Wen-Hung Chung: Department of Dermatology, Beijing Tsinghua Chang Gung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, China
Wen-Hung Chung: School of Medicine, Shanghai Jiao Tong University, Shanghai, China

DOI: https://doi.org/10.3389/fphar.2020.00969
Journal volume & issue: Vol. 11

Abstract

Read online

Severe cutaneous adverse reactions (SCAR), such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug rash with eosinophilia and systemic symptoms (DRESS), are idiosyncratic and unpredictable drug-hypersensitivity reactions with a high-mortality rate ranging from 10% to over 30%, thus causing a major burden on the healthcare system. Recent pharmacogenomic studies have revealed strong associations between SCAR and the genes encoding human-leukocyte antigens (HLAs) or drug-metabolizing enzymes. Some of pharmacogenetic markers have been successfully applied in clinical practice to protect patients from SCAR, such as HLA-B*15:02 and HLA-A*31:01 for new users of carbamazepine, HLA-B*58:01 for allopurinol, and HLA-B*57:01 for abacavir. This article aims to update the current knowledge in the field of pharmacogenomics of drug hypersensitivities or SCAR, and its implementation in the clinical practice.

Published in Frontiers in Pharmacology

ISSN: 1663-9812 (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Therapeutics. Pharmacology
Website: http://journal.frontiersin.org/journals/pharmacology

About the journal

Abstract

Keywords